Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study.

Nowak, Richard J; Muppidi, Srikanth; Beydoun, Said R; O'Brien, Fanny L; Yountz, Marcus; Howard, James F

Nowak, Richard J; Muppidi, Srikanth; Beydoun, Said R; O'Brien, Fanny L; Yountz, Marcus; Howard, James F.

Afiliación

Nowak RJ; Department of Neurology, Yale University School of Medicine, New Haven, CT, United States.
Muppidi S; Department of Neurology and Neurosciences, Stanford University School of Medicine, Stanford, CA, United States.
Beydoun SR; Department of Neurology, University of Southern California, Los Angeles, CA, United States.
O'Brien FL; Alexion Pharmaceuticals, Boston, MA, United States.
Yountz M; Alexion Pharmaceuticals, Boston, MA, United States.
Howard JF; Department of Neurology, University of North Carolina, Chapel Hill, NC, United States.

Front Neurol ; 11: 556104, 2020.

Article en En | MEDLINE | ID: mdl-33329303

Palabras clave

acetylcholine receptor; eculizumab; immunosuppressive therapy; myasthenia gravis; refractory

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Front Neurol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google